Lakefront Biotherapeutics NV (LKFT) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings. Latest close $34.07 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Greenlight Capital — 1 tracked fund hold LKFT. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Greenlight Capital | 0.37% | 482,746 | HELD Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +16.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 77 of 8,857 filers |
| Long-only filers among them | 77 |
| Change vs 2026 Q1 | -12 net · 77 entered · 89 exited |
| Shares reported, all filers | 32,057,086 |
| Reported value, all filers | $972.6M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | 1.1B EUR |
| Net income · FY2025 | 320.9M EUR |
| Total assets · FY2025 | 3.4B EUR |
| Shares outstanding | 65,897,071 |
| Market cap (at latest close) | $2.2B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Oct 15, 2026 | 1,416,118 |
| Share of shares outstanding | 2.15% |
| Days to cover | 4.77 |
Shares short at recent settlements — Jul 31, 2026: 2.5M · Aug 14, 2026: 3.0M · Aug 31, 2026: 3.3M · Sep 15, 2026: 3.4M · Sep 30, 2026: 3.3M · Oct 15, 2026: 1.4M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 18 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jul 28, 2025 | SCHEDULE 13D/A | +4.8% (close Jul 29, 2025 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jul 29, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | Madison Avenue International LP | SC 13G | 3,606,203 | 5.5% | Jun 15, 2026 | SEC filing |
| Oct 29, 2025 | TANG CAPITAL MANAGEMENT, LLC | SC 13G | 5,559,674 | 8.4% | Oct 27, 2025 | SEC filing |
| Jul 28, 2025 | EcoR1 Capital, LLC | SC 13D/A | 8,714,522 | 13.2% | Jul 24, 2025 | SEC filing |
| May 19, 2025 | EcoR1 Capital, LLC | SC 13D/A | 7,803,202 | 11.8% | May 15, 2025 | SEC filing |
| Feb 14, 2025 | TANG CAPITAL MANAGEMENT, LLC | SC 13D | 4,910,525 | 7.5% | Feb 7, 2025 | SEC filing |
| Jan 10, 2025 | Gilead Sciences, Inc. | SC 13D/A | 20,981,010 | 29.9% | Jan 7, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold LKFT — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
No Form 8-K filings for this ticker in the index (Jan 2023 – present).
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on LKFT
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.